Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

3.35
-0.0100-0.30%
Pre-market: 3.33-0.0200-0.60%08:58 EDT
Volume:3.08M
Turnover:10.27M
Market Cap:649.90M
PE:-4.41
High:3.43
Open:3.35
Low:3.29
Close:3.36
52wk High:6.44
52wk Low:2.56
Shares:194.00M
Float Shares:164.00M
Volume Ratio:0.74
T/O Rate:1.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7600
EPS(LYR):-0.9999
ROE:-28.87%
ROA:-17.20%
PB:1.37
PE(LYR):-3.35

Loading ...

U.S. Research ROUNDUP-Boeing, Coca-Cola, PayPal

Reuters
·
Jul 29

U.S. Stocks on the MOVE-Visa, CMS Energy, Ecolab

Reuters
·
Jul 29

Barclays says trial data highlights meaningful opportunity for Altimmune in AUD

TIPRANKS
·
Jul 29

H.C. Wainwright sees ‘clear Phase 2 win’ for Altimmune

TIPRANKS
·
Jul 28

Leerink remains bullish on Altimmune following ‘positive’ AUD trial results

TIPRANKS
·
Jul 28

Unusually active option classes on open July 28th

TIPRANKS
·
Jul 28

Altimmune's Investigational Alcohol Use Disorder Drug Meets Primary Endpoint in Phase 2 Study

MT Newswires Live
·
Jul 28

Altimmune Shares Jump Premarket After Positive Results in Phase 2 Trial of Pemvidutide

Dow Jones
·
Jul 28

Altimmune Jumps as Experimental Obesity Drug Shows Benefit in Alcohol Use Disorder Study

Reuters
·
Jul 28

Altimmune Shares up 17% Premarket as Co's Drug Meets Main Goal of Mid-Stage Study for Alcohol Use Disorder

THOMSON REUTERS
·
Jul 28

Altimmune's Drug Meets Main Goal of Mid-stage Study for Alcohol Use Disorder

Reuters
·
Jul 28

Altimmune - to Request End-of-Phase 2 Meeting with FDA for Pemvidutide in AUD

THOMSON REUTERS
·
Jul 28

Altimmune - Pemvidutide Meets FDA-Recognized Registrational Endpoints in Phase 2 Trial

THOMSON REUTERS
·
Jul 28

Altimmune Announces Positive Topline Results from Reclaim Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

THOMSON REUTERS
·
Jul 28

Altimmune - Pemvidutide 2.4 Mg Achieves Significant Reduction in Heavy Drinking Days in Phase 2 Trial

THOMSON REUTERS
·
Jul 28

Altimmune - Pemvidutide Demonstrates Generally Favorable Tolerability Profile in Phase 2 Trial

THOMSON REUTERS
·
Jul 28

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

GlobeNewswire
·
Jul 15

Unusually active option classes on open June 24th

TIPRANKS
·
Jun 24

Altimmune Initiated at Outperform by Leerink Partners

Dow Jones
·
Jun 22

Leerink Partners Initiates Altimmune at Outperform With $10 Price Target

MT Newswires Live
·
Jun 22